Lataa...
Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential
HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20–30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This...
Tallennettuna:
| Julkaisussa: | Immunotherapy |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Future Medicine Ltd
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5967360/ https://ncbi.nlm.nih.gov/pubmed/27605070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2016-0052 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|